Uncategorized
Immune Response Gene Variants Tied to Earlier Breast Cancer in BRCA1 Carriers
Researchers headed by a team at Tel Aviv University have discovered that damaging variants in genes involved in a rapid immune response (innate immunity) are significantly linked to earlier breast cancer (BC) onset in carriers of the harmful BRCA1 genetic mutation. The team carried out whole exome sequencing (WES) of hundreds of Ashkenazi Jewish women with the BRCA1 risk variant, and found that the strongest association with earlier BC onset was for genes involved in the activation of natural killer (NK) cells, which serve as the body’s rapid first line defense against viruses and cancer.
The findings prompt the researchers to suggest that more refined, personalized risk prediction models may be needed for carriers of the mutant BRCA1 gene, as although this mutation strongly boosts their risk of breast cancer, age at diagnosis varies considerably.
The team reported on the findings in Journal of Medical Genetics, in a paper titled “Damaging missense variants in innate immunity genes are associated with earlier age of breast cancer onset in BRCA1 185delAG carriers,” in which they concluded “To the best of our knowledge, our study is the first large-scale WES analysis aimed at identifying genetic modifiers of BC risk in BRCA1 PV carriers … Our findings highlight a novel role for innate immune pathways as potential modifiers of BC risk in BRCA1 carriers.”
BRCA1 is one of two prominent breast cancer susceptibility genes, the authors explained. “Women harboring a pathogenic variant (PV) in BRCA1 have an estimated 60–80% lifetime risk of developing BC, along with a substantially elevated risk (30–40%) of ovarian cancer.”
Surgical removal of the breasts, fallopian tubes, and ovaries mitigates the risk, but because the age at which breast cancer develops in carriers is highly variable, even amongst those with the same genetic BRAC1 mutation, it’s difficult to know when this life changing procedure should be carried out, they commented. “Although penetrance for BC in BRCA1 carriers is high, it is incomplete, and age at BC diagnosis among BRCA1 carriers varies widely, even among carriers of identical PV in the same families.”
This variation in disease onset suggests that other modifying factors might be influential, including impaired immunity, because of the pivotal role the immune system has in the development and surveillance of cancer, the team suggested. They hypothesized that “… impaired immune function may also modify BC risk among BRCA1 PV carriers.”
To explore this further, the team studied whole exome sequencing information from 321 Ashkenazi Jewish women, among whom the prevalence of BRCA1 mutations is around five to six times higher than it is among other ethnic groups worldwide. The women were all carrying the same BRCA1 mutation (185delAG) and 98 of them had been diagnosed with breast cancer. Their average age at diagnosis was 41.5 years, but ranged from 26 to 75 years. “Leveraging a large whole-exome sequencing (WES) cohort of Israeli women carrying the BRCA1 185delAG AJ founder PV, we examined whether carrying additional putatively damaging variants in genes involved in distinct arms of the immune system was associated with age at BC diagnosis,” they commented.
Whole exome sequencing reads the most crucial 1–2% of a person’s DNA—the exome— which contains around 85% of mutations known to cause specific medical conditions. The researchers’ whole exome sequencing data revealed that additional likely damaging mutations (missense variants) in genes involved in innate immunity were significantly associated with earlier onset of breast cancer.
Mutations in the genes involved in natural killer cell activation were most strongly associated with earlier disease onset, conferring a risk more than 3.5 times greater. “We found that the presence of additional putatively damaging missense variants in genes involved in innate immunity was significantly associated with earlier BC diagnosis,” they stated. “This effect was noted for several overlapping gene sets; the strongest one was for the genes annotated as involved in the activation of NK cells.” They pointed out that the risk-modifying effect they round was specific to genes involved in innate immunity. There was no significant association identified for genes related to the adaptive immune system.
“In summary, our findings in the Israeli cohort of identical BRCA1 PV carriers highlight a potential role for innate immune pathways as modifiers of BRCA1 penetrance and may support the development of more refined, personalized BC risk prediction models for BRCA1 PV carriers,” the investigators wrote. However, they cautioned, “It remains to be determined whether these preliminary findings can be replicated in independent, ethnically diverse, larger cohorts of carriers of heterogeneous PVs in BRCA1.”
The post Immune Response Gene Variants Tied to Earlier Breast Cancer in <i>BRCA1</i> Carriers appeared first on GEN – Genetic Engineering and Biotechnology News.
Uncategorized
Laser‑Driven Phase Contrast Enhances Cryo‑EM Resolution of Small Proteins
You know when you are at the eye doctor getting an updated prescription, and suddenly the world snaps into sharper focus? Physicists at the University of California (UC), Berkeley, have now done something similar for electron microscopy. By introducing phase contrast into a cryo‑electron microscope, they have delivered dramatically sharper images of some of biology’s smallest and most elusive proteins.
The advance comes from a new laser phase plate (LPP), described in the paper “Laser phase plate improves structure determination of small proteins by cryo‑EM,” which was published recently in Science. Led by physicist Holger Mueller, PhD, of UC Berkeley and Lawrence Berkeley National Laboratory, the team demonstrated that a laser‑driven phase plate can overcome one of cryo‑EM’s most persistent limitations: poor contrast for small proteins.

Cryo‑EM has transformed structural biology over the past decade, earning a Nobel Prize in 2017 for enabling high‑resolution structures without crystallization. But despite its impact, the technique still struggles with proteins below ~70 kilodaltons—a size range that includes about 90% of the human proteome. “Because of signal-to-noise limitations, the majority of human and animal proteins are too small to be analyzed by these methods [cryo-EM and cryoelectron tomography]. The increase in signal-to-noise ratio provided by this laser phase plate is expected to overcome these important limitations.”
The new LPP begins to address that problem. The LPP uses an intense, continuous‑wave laser to shift the phase of the electron beam itself. This produces true phase contrast without dimming or destabilizing the beam. Mueller described the laser focus as “75 kilowatts focused to a few microns… That’s more powerful than what you use for welding. It has more power than a military laser. It builds up the brightest continuous laser focus ever.”
Installed in a custom Thermo Fisher Titan Krios, the LPP immediately improved the clarity and resolvability of small proteins, including hemoglobin, which sits at the lower limit of what today’s cryo‑EM instruments can handle. As the authors wrote in the abstract: “Here, we show that the laser phase plate (LPP)… enhances the resolution in single-particle reconstruction of small proteins by improving specimen-motion correction, recovery of information from the early frames, as well as particle visualization, 3D classification, and alignment.”

These improvements were achieved using standard defocus ranges and reconstruction workflows. “For the most challenging cases—small particles, bad specimens—the laser produces a very considerable advantage,” Mueller said.
The impact extends beyond single‑particle analysis. Cryo‑electron tomography (cryo‑ET), which assembles multiple angular views of a molecule or protein into a three-dimensional image, stands to benefit even more. “With cryo-ET, we’re looking at small, very complicated cellular material that’s incredibly crowded inside the cell,” said Bridget Carragher, PhD, founding technical director of imaging at Biohub. “It’s like a forest of trees, and you’re trying to find one leaf on one tree in there. Cryo-ET needs a dramatic step forward in contrast, so we can start to see what’s going on inside the cell. That’s what the laser phase plate promises to give us.”
Biohub is developing a dual‑laser version of the system, designed to reduce component wear and minimize aberrations. Meanwhile, Mueller’s team is pushing toward imaging proteins as small as 17 kilodaltons, a threshold that would open access to vast regions of the human proteome previously invisible to cryo‑EM.
“This technology is a step function change for biology,” said Stephani Otte, PhD, Biohub’s vice president of imaging science. “What was once invisible will become visible—and that changes everything about how we understand disease.”
“The bottom line is, if you have a large protein and a really good sample—a fresh one or one frozen without bubbles, for example—you may not need the phase plate to get a single, high-quality image. But for a small protein and a bad sample, laser-on is best,” Mueller said. “This could fill an enormous gap in our knowledge of protein structures that can’t be crystallized or are too small for today’s cryo-EM. And it will be revolutionary for cryo-ET.”
The post Laser‑Driven Phase Contrast Enhances Cryo‑EM Resolution of Small Proteins appeared first on GEN – Genetic Engineering and Biotechnology News.
Uncategorized
STAT+: Updated: Tracking RFK Jr.’s promises to remake health in America
Updated June 11, 2026
WASHINGTON — A pledge to “Make America Healthy Again” earned Robert F. Kennedy Jr. his job atop U.S. health agencies a year and some change ago. He’s now had the opportunity to turn his words into action, with mixed results.
“All one needs” to prove the health secretary’s attentiveness is to “review my unprecedented list of accomplishments on a wide range of issues, all of which I drove,” Kennedy posted on X on Wednesday in response to a journalist.
Updated June 11, 2026
WASHINGTON — A pledge to “Make America Healthy Again” earned Robert F. Kennedy Jr. his job atop U.S. health agencies a year and some change ago. He’s now had the opportunity to turn his words into action, with mixed results.
“All one needs” to prove the health secretary’s attentiveness is to “review my unprecedented list of accomplishments on a wide range of issues, all of which I drove,” Kennedy posted on X on Wednesday in response to a journalist.
Uncategorized
An obesity drug deep-dive, and peptides move mainstream
Can any of the new obesity medications in development stand out from the pack? Which company just broke records with its IPO? And will the Food and Drug Administration allow greater access to experimental peptides?
We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast.
-
Uncategorized9 years agoThese ’90s fashion trends are making a comeback in 2017
-
Uncategorized9 years agoAccording to Dior Couture, this taboo fashion accessory is back
-
Endpoints News3 months ago
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
-
Uncategorized9 years agoPhillies’ Aaron Altherr makes mind-boggling barehanded play
-
Uncategorized9 years agoUber and Lyft are finally available in all of New York State
-
Contributors9 years agoThe final 6 ‘Game of Thrones’ episodes might feel like a full season
-
Uncategorized9 years agoSteph Curry finally got the contract he deserves from the Warriors
-
Uncategorized9 years agoThe old and New Edition cast comes together to perform